ACG in San Antonio on May 23, 2017: Maria Zannes, CEO of bioAffinity Technologies, Inc.

Share:
Image
Maria Zannes

Event Details

When:

May 23, 2017 11:30 AM - 1 PM CDT

Add to Calendar

Overview

Body

Online registration is now closed.  Walk-ins may be accommodated, if space becomes available based on no-shows, at the following rates:  ACG Member price: 40./Non-ACG Member price: 65. 
This event will take place @ the Plaza Club in the Frost Bank building @ 100 W. Houston St. Suite 2100 in San Antonio. 

Complimentary self-parking for this event is available in the parking garage of the Frost Bank building.
 
Your registration for this event acts as an audio/video release and includes your permission for ACG Central Texas to use your image and comments captured on audio, video or photographic formats while attending the event for marketing and promotional purposes. For further information please contact: Sara Singer - ACG Central Texas Chapter Executive @ acgcentraltexas@acg.org or 512-970-0417. 
  

Cancellation Policy – Cancellations received in writing to acgcentraltexas@acg.org by 5pm, May 22nd will receive a full refund. There are no refunds for cancellations received after 5pm on May 22nd. If you are an ACG Member unable to attend, you can transfer your registration to another person for this same event. If the person attending in your place is not an ACG Member, they will need to pay an additional fee to bring them up to the non-member rate to attend.

Speakers

Image
Maria Zannes

Maria Zannes

bioAffinity Technologies, Inc.
CEO

Maria Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. She was instrumental in securing significant public funding for private research into lung cancer, including the approval for a clinical trial of bioAffinity’s early lung cancer diagnostic assay. Her experience on Capitol Hill and as a lobbyist in more than a dozen state legislatures, including her prior positions as President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX), provides Ms. Zannes with an appreciation of how industry can leverage government programs to advance new technologies. She was General Manager of ECOS Corporation and was responsible for the formation and development of the company that later became a subsidiary of Burlington Environmental. Ms. Zannes began her career as a journalist and is licensed to practice law in New Mexico and is a non-practicing member of the Washington State Bar. She has been awarded the Lifetime Achievement Award by the American Society of Mechanical Engineers and the Earth Engineering Center Award of Columbia University. She continues to serve as a research associate with Columbia University Earth Engineering Center and is the co-founder of two engineering research centers at the university. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.

 
bioAffinity Technologies, Inc. is a privately held developmental-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor, and treat many cancers. CyPath® Lung, bioAffinity Technologies’ initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Hosted by: ACG
Chapter
Austin/San Antonio
Share: